NCT05142553View on ClinicalTrials.gov

Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

PHASE2CompletedINTERVENTIONAL
Enrollment

887

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

May 29, 2023

Study Completion Date

May 29, 2023

Conditions
COVID-19SARS-CoV-2 Acute Respiratory Disease
Interventions
BIOLOGICAL

COVID-19 Vaccine HIPRA

Subjects will receive one injection of COVID-19 Vaccine HIPRA

BIOLOGICAL

Cominarty (Pfizer-BioNtech)

Subjects will receive one injection of Cominarty Vaccine

Trial Locations (10)

17007

Hospital Universitari Dr. Josep Trueta, Girona

17170

Hospital Clinic de Barcelona, Barcelona

28007

Hospital Gregorio Marañón, Madrid

28046

Hospital Universitario La Paz, Madrid

28805

Hospital Principe de Asturias, Meco

29010

Hospital Regional Universitario de Málaga, Málaga

46010

Hospital Clínico de Valencia, Valencia

48903

Hospital de Cruces, Barakaldo

08916

Hospital Germans Trias I Pujol, Badalona

08035

Hospital Vall Hebron, Barcelona

Sponsors

Collaborators (1)

Laboratorios Hipra, S.A.
All Listed Sponsors
collaborator

Laboratorios Hipra, S.A.

INDUSTRY

lead

Hipra Scientific, S.L.U

INDUSTRY

NCT05142553 - Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. | Biotech Hunter | Biotech Hunter